Drugs / BMG0703
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05787600 | Mar → Apr 2023 | chronic gingivitis | University of Baghdad | Completed | No outcome recorded |
| Phase 3 | NCT04438421 | Jun → Jul 2020 | chronic gingivitis | University of Milan | Unknown | No outcome recorded |
| Phase 3 | NCT04446533 | Jun → Jul 2020 | chronic gingivitis, periodontitis | University of Milan | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMG0703 | “After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe.” NCT04446533 ↗1“Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures.” NCT04438421 ↗ |
| Known as | Perhyal rinse | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05787600 ↗ |
| Route | Other | “After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe.” NCT04446533 ↗ |